Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,552 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mixed-Genotype HCV Direct Acting Antiviral Outcomes: A CANUHC Analysis.
Imsirovic H, Macphail G, Conway B, Fraser C, Borgia S, Smyth D, Wong A, Vachon ML, Webster D, Liu H, Feld J, Lee S, Cooper C; Canadian Network Undertaking against Hepatitis C (CANUHC) Cohort Investigator Team. Imsirovic H, et al. Among authors: fraser c. J Viral Hepat. 2024 Nov;31(11):775-779. doi: 10.1111/jvh.13995. Epub 2024 Aug 12. J Viral Hepat. 2024. PMID: 39135466
Characterization of HCV-infected people who inject drugs (PWID) in the setting of clinical care in Canada (CAPICA): A retrospective study.
Conway B, Bruneau J, Cooper C, Steingart C, Fraser C, Stewart K, Deshaies L, Thomas R, Webster D, Macphail G, Powis J, Cox J, Feld JJ, McGovern ME, Trepanier JB, Drolet M. Conway B, et al. Among authors: fraser c. Can Liver J. 2020 Nov 17;3(4):358-371. doi: 10.3138/canlivj-2020-0004. eCollection 2020 Fall. Can Liver J. 2020. PMID: 35990509 Free PMC article.
The Z-Profile Study: a multicenter, retrospective cohort study to assess the real-world use and effectiveness of elbasvir/grazoprevir in Canadian adult patients with chronic hepatitis C.
Tam E, Tremblay J, Fraser C, Conway B, Ramji A, Borgia S, Tsoi K, Yoshida EM, Rajendran B, Macphail G, Wong A, Cooper C, Patel K, Puglia M, Stewart K, Trottier B, Deshaies L, Doucette K, Ghali P, Lee SS, Halsey-Brandt J, Trepanier JB. Tam E, et al. Among authors: fraser c. Can Liver J. 2020 Aug 20;3(3):251-262. doi: 10.3138/canlivj-2019-0029. eCollection 2020 Summer. Can Liver J. 2020. PMID: 35992533 Free PMC article.
Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs.
Cunningham EB, Hajarizadeh B, Amin J, Hellard M, Bruneau J, Feld JJ, Cooper C, Powis J, Litwin AH, Marks P, Dalgard O, Conway B, Moriggia A, Stedman C, Read P, Bruggmann P, Lacombe K, Dunlop A, Applegate TL, Matthews GV, Fraser C, Dore GJ, Grebely J. Cunningham EB, et al. Among authors: fraser c. Clin Infect Dis. 2021 Apr 26;72(8):1392-1400. doi: 10.1093/cid/ciaa253. Clin Infect Dis. 2021. PMID: 32166305
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study.
Cunningham EB, Amin J, Feld JJ, Bruneau J, Dalgard O, Powis J, Hellard M, Cooper C, Read P, Conway B, Dunlop AJ, Norton B, Litwin AH, Hajarizadeh B, Thurnheer MC, Dillon JF, Weltman M, Shaw D, Bruggmann P, Gane E, Fraser C, Marks P, Applegate TL, Quiene S, Siriragavan S, Matthews GV, Dore GJ, Grebely J; SIMPLIFY study group. Cunningham EB, et al. Among authors: fraser c. Int J Drug Policy. 2018 Dec;62:14-23. doi: 10.1016/j.drugpo.2018.08.013. Epub 2018 Oct 22. Int J Drug Policy. 2018. PMID: 30352330 Clinical Trial.
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.
Grebely J, Conway B, Cunningham EB, Fraser C, Moriggia A, Gane E, Stedman C, Cooper C, Castro E, Schmid P, Petoumenos K, Hajarizadeh B, Marks P, Erratt A, Dalgard O, Lacombe K, Feld JJ, Bruneau J, Daulouede JP, Powis J, Bruggmann P, Matthews GV, Kronborg I, Shaw D, Dunlop A, Hellard M, Applegate TL, Crawford S, Dore GJ; D3FEAT Study Group. Grebely J, et al. Among authors: fraser c. Int J Drug Policy. 2018 Dec;62:94-103. doi: 10.1016/j.drugpo.2018.10.004. Epub 2018 Oct 29. Int J Drug Policy. 2018. PMID: 30384028
Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy.
Cunningham EB, Hajarizadeh B, Amin J, Litwin AH, Gane E, Cooper C, Lacombe K, Hellard M, Read P, Powis J, Dalgard O, Bruneau J, Matthews GV, Feld JJ, Dillon JF, Shaw D, Bruggmann P, Conway B, Fraser C, Marks P, Dore GJ, Grebely J; SIMPLIFY and D3FEAT study groups. Cunningham EB, et al. Among authors: fraser c. Clin Infect Dis. 2020 Oct 23;71(7):e115-e124. doi: 10.1093/cid/ciz1089. Clin Infect Dis. 2020. PMID: 31677262 Free article.
Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs.
Cheng Q, Cunningham EB, Shih S, Amin J, Bruneau J, Artenie AA, Powis J, Litwin AH, Cooper C, Dalgard O, Hellard M, Bruggmann P, Marks P, Lacombe K, Stedman C, Read P, Hajarizadeh B, Dunlop AJ, Conway B, Feld JJ, Dore GJ, Grebely J; SIMPLIFY and D3FEAT Study Groups. Cheng Q, et al. Value Health. 2023 Jun;26(6):883-892. doi: 10.1016/j.jval.2022.12.016. Epub 2023 Jan 13. Value Health. 2023. PMID: 36646278 Free article.
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, Amin J, Bruneau J, Hellard M, Litwin AH, Marks P, Quiene S, Siriragavan S, Applegate TL, Swan T, Byrne J, Lacalamita M, Dunlop A, Matthews GV, Powis J, Shaw D, Thurnheer MC, Weltman M, Kronborg I, Cooper C, Feld JJ, Fraser C, Dillon JF, Read P, Gane E, Dore GJ; SIMPLIFY Study Group. Grebely J, et al. Among authors: fraser c. Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161. doi: 10.1016/S2468-1253(17)30404-1. Epub 2018 Jan 6. Lancet Gastroenterol Hepatol. 2018. PMID: 29310928 Free article. Clinical Trial.
Virological Outcomes After Switching to Abacavir/Lamivudine/Dolutegravir Combined with Adherence Support in People Living with HIV with Poor Adherence: A Phase IV, Multicentre Randomized Prospective Open Label Study (TriiADD-CTN 286).
Klein MB, Young J, Ortiz-Paredes D, Wang S, Walmsley S, Wong A, Martel-Laferrière V, Pick N, Conway B, Angel J, Baril JG, Fraser C, Lebouché B, Tan DHS, Sandre R, Trottier S, Peiris H, Jayaraman J, Singer J; CTN 286 Study Investigators. Klein MB, et al. Among authors: fraser c. Patient Prefer Adherence. 2022 Dec 13;16:3267-3281. doi: 10.2147/PPA.S379065. eCollection 2022. Patient Prefer Adherence. 2022. PMID: 36536672 Free PMC article.
2,552 results